Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, we discuss how WuXi AppTec has bounced back, despite the tremendous pressure it had been under due to the BIOSECURE Act. Also, we see positive lung cancer data from Nuvalent, and we highlight new two European venture funds.

The need-to-know this morning

Johnson & Johnson said it is acquiring Halda Therapeutics , a developer of cancer drugs, for $3.05 billion. Halda’s lead pipeline product is a treatment for prostate cancer.

WuXi AppTec thrives as U.S. eases pressure

After nearly two years under threat from Congress, WuXi AppTec is emerging stronger: U.S. lawmakers ultimately stripped company names from the BIOSECURE Act, defusing fears th

See Full Page